¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"gonococcal complement fixation test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • aptitude test
    Àû¼º°Ë»ç
  • articulation test
    ¹ßÀ½°Ë»ç
  • association test
    ¿¬»ó°Ë»ç
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • autohemolysis test
    ÀÚ°¡¿ëÇ÷°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • adsorption test
    ÈíÂø½ÃÇè, ºÎÂø°Ë»ç
  • afterimage test
    ÀÜ»ó°Ë»ç
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • agglutination test
    ÀÀÁý°Ë»ç
  • air conduction test
    °ø±âÀüµµ°Ë»ç
  • alkali denaturation test
    ¾ËÄ®¸®º¯¼º°Ë»ç
  • alternate cover test
    ±³´ë°¡¸²°Ë»ç
  • absorption test
    Èí¼ö½ÃÇè, Èí¼ö°Ë»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • thematic apperception test
    ÁÖÁ¦Åë°¢°Ë»ç
  • tilt test
    ±â¸³°æ»ç°Ë»ç
  • treadmill test
    Æ®·¹µå¹Ð°Ë»ç
  • triple test
    »ïÁß°Ë»ç
  • triple marker test
    »ïÁßÇ¥Áö°Ë»ç
  • tuberculin test
    Åõº£¸£Ä𸰰˻ç
  • urea breath test
    ¿ä¼Ò³¯¼û°Ë»ç
  • vestibular function test
    ¾È¶ã±â´É°Ë»ç, ÀüÁ¤±â´É°Ë»ç
  • visual acuity test
    ½Ã·Â°Ë»ç
  • water deprivation test
    ¼öºÐÁ¦ÇѰ˻ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • achievement test
    ¼ºÃëµµ°Ë»ç
  • acid challenge test
    »êÅõ¿©°Ë»ç
  • acid elution slide test
    »ê¿ëÃâ½½¶óÀ̵å°Ë»ç
  • adsorption test
    ÈíÂø½ÃÇè, ºÎÂø°Ë»ç
  • afterimage test
    ÀÜ»ó°Ë»ç
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • agglutination test
    ÀÀÁý°Ë»ç
  • air conduction test
    ±âµµ°Ë»ç, °ø±âÀüµµ°Ë»ç
  • alkali denaturation test
    ¾ËÄ®¸®º¯¼º°Ë»ç
  • alternate cover test
    ±³´ë°¡¸²°Ë»ç
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º½ÃÇè
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Congo red test
    Äá°íÀû½ÃÇè.»ýÈ­Äá°í·¹µå½ÃÇè.
  • Continuous Performance Test
    Áö¼Ó¼öÇà °Ë»ç
  • Coombs consumption test
    Äñ½º¼Ò¸ð°Ë»ç
  • Cosyntropin stimulation test
    ÄÚ½ÅÆ®·ÎÇÉ ÀڱؽÃÇè
  • Cuboni s test
    Äíº¸´Ï½ÃÇè.
  • Cytronbergs test
    ½ÃÆ®·Ðº£¸£Å©½ÃÇè.
  • DAT =>direct antiglobulin test
    Á÷Á¢ Çױ۷κҸ°½ÃÇè
  • DDST=Denver developmental screening test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç
  • DNase test
    DNA ºÐÇØÈ¿¼Ò½ÃÇè
  • DST=dexamethasone supression test
    µ¦»ç¸ÞŸ¼Õ ¾ïÁ¦°Ë»ç
  • Dehydration test
    Å»¼ö°Ë»ç
  • Denver Developmental Screening Test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç(Û¡Ó¹ðàÞÛËþÞÛ)
  • Denver developmental screening test
    µ§¹ö¹ßÀ°¼±º°¹ý.
  • Dick test
    µñÅ©½ÃÇè
  • Dick test
    µñ °Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • complement mediated lysis
    º¸Ã¼Áß°³¼º ¿ëÇØ.
  • complement mediated lysis
    º¸Ã¼¸Å°³ ¿ëÇØ.
  • complement profile
    º¸Ã¼Ãø¸é»ó(ö°ØüßÀ)
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement receptor 1
    º¸Ã¼ ¼ö¿ëü 1
  • complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • complement splitting
    º¸Ã¼ºÐÇØ(¡­ÝÂú°).
  • complement system
    º¸Ã¼°è
  • complement system
    º¸Ã¼°è(¡­Í§)
  • complement system, alternative pathway
    ´ëü°æ·Î(ÓÛôðÌèÖØ)
  • complement system, classic pathway
    ÀüÇüÀû °æ·Î(îðúþîÜÌèÖØ)
  • complement typing
    º¸Ã¼Çüº°È­(úþܬûù)
  • complement unit
    º¸Ã¼´ÜÀ§(¡­Ó¤êÈ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • ketostix test
    ÄÉÅ佺ƽ°Ë»ç(ËþÞÛ)
  • lactose tolerance test
    "¶ôÅ佺 ºÎÇϰ˻ç(ݶùÃËþÞÛ), ¶ôÅ佺³»¼º°Ë»ç(Ò±àõËþÞÛ)"
  • liver function test
    °£±â´É °Ë»ç(ÊÜÐüÒöËþÞÛ)
  • load test
    ºÎÇϰ˻ç(ݶùÃËþÞÛ)
  • Luria-Delbrueck fluctuation test
    ·ç¸®¾Æ-µ¨ºê¸¯ ¿äµ¿½ÃÇè(èôÔÑãËúÐ)
  • metyrapone test
    ¸ÞƼ¶óÆù°Ë»ç(ËþÞÛ)
  • Molisch test
    ¸ô¸®½¬ ½ÃÇè(ãËúÐ)
  • Morner's test
    ¸ð³Ê ½ÃÇè(ãËúÐ)
  • murexide test
    ¹Â·¡½Ãµå°Ë»ç(ËþÞÛ)
  • patch test
    ÆÐÄ¡½ÃÇè(ãËúÐ)
  • phase test
    »ó½ÃÇè(ßÓãËúÐ)
  • phenolsulfonphthalein test
    Æä³î¼³ÆùÅ»·¹ÀÎ ½ÃÇè(ãËúÐ)
  • phenylalanine load test
    Æä´Ò¾Ë¶ó´Ñ ºÎÇϽÃÇè(ݶùÃãËúÐ)
  • phenylalanine tolerance test
    Æä´Ò¾Ë¶ó´Ñ ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • PSP test
    (å²) Phenolsulfonphthalein test
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
NGU Non-Gonococcal Urethritis
DGI dentinogenesis imperfecta; disseminated gonococcal infection
GADS gonococcal arthritis/dermatitis syndrome
GCB gonococcal base
GCU gonococcal urethritis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
C3 Complement 3
CCP Complement Control Protein
CF Complement Fixing
CR1 Complement Receptor 1
CDC Complement dependent cytotoxicity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • augmented histamine test
    °­È­ È÷½ºÅ¸¹Î Áõ°­ ½ÃÇè
    12½Ã°£ ´Ü½Ä ÈÄ¿¡ ÀÜ·ù À§ ³»¿ë¹°À» ÈíÃâ±â·Î »¡¾Æ³½ ÈÄ, 15ºÐ °£°ÝÀ¸·Î 1½Ã°£ µ¿¾È ±âÃÊ À§ ºÐºñ¾×À» äÃëÇÑ´Ù. äÃë¿Ï·á 30ºÐ Àü¿¡ Àû´ç·®ÀÇ Ç×È÷½ºÅ¸¹ÎÀ» ±ÙÀ° ³»¿¡ Åõ¿©ÇÑ´Ù. ±âÃÊ ºÐºñ äÃë°¡ ³¡³¯ ¶§ »ê¼º Àλê È÷½ºÅ¸¹ÎÀ» ÆÄÇÏÁÖ»çÇϰí, À§ ³»¿ë¹°À» 15ºÐ °£°ÝÀ¸·Î 1½Ã°£ µ¿¾È äÃëÇÑ´Ù. °¢ 15ºÐ°£ÀÇ Ç¥º»¹°¿¡ ´ëÇÑ ºÎÇÇ,
  • automated reagin test
    ÀÚµ¿È­ ¸®¾ÆÁø ½ÃÇè
  • Ayer's test
    ¿¡ÀÌ¾î ½ÃÇè
  • Babinski-Weil test
    ¹Ùºó½ºÅ°-¿ÍÀÏ ½ÃÇè
  • Bacitracin differential disk test
    ¹Ù½ÃÆ®¶ó½Å °¨º°ÆÇ ½ÃÇè, ¹Ù½ÃÆ®¶ó½Å °¨º° ¿øÆÇ ½ÃÇè
  • bacteriolytic test
    ¿ë±Õ ½ÃÇè
  • bacteriophage neutralization test
    ¹ÚÅ׸®¿À ÆÄ¾ÆÁö ÁßÈ­ ½ÃÇè
  • Baermann test
    º£¾î¸¸ ½ÃÇè
  • bar-reading test
    ¹Ù-¸®µù ½ÃÇè
    ¾ç¾È½Ã¿Í ÀÔü ½Ã¿¡ ´ëÇÑ ½ÃÇèÀ¸·Î¼­, ¾çÂÊ ´«°ú ÀμâµÈ ÆäÀÌÁö¿Í »çÀÌ Áß°£Âë¿¡ ÀÚ¸¦ ³õ´Â´Ù. À̰ÍÀº ¶ÇÇÑ ÀÔü½ÃÀÇ ÈÆ·Ã¿¡µµ ÀÌ¿ëµÈ´Ù.
  • barany's test
    ¹Ù´Ï´Ï ¿Âµµ ½ÃÇè
  • Bardach's test
    ¹Ù¸£´ÙÇÏ ´Ü¹éÁú °ËÃâ¹ý
  • Bareggi's test
    ¹Ù·º±â ½ÇÇè
    ƼǪ½º ȯÀÚ¿¡¼­´Â äÇ÷ ÈÄÀÇ Ç÷º´ ¼öÃàÀÌ ºÒ·®ÇÏ´Ù.
  • Barfood's test
    ¹Ù¸£Ç£µå ½ÇÇè
    ȯ¿ø´çÀÇ °ËÃâ ½ÇÇè.
  • Barral's test
    ¹Ù¶ö ½ÃÇè
    20% ¿À¸£ÅäÆä³î¼³Æù»êÀ¸·Î ¿ä¸¦ ÁßÃþÇÒ ¶§ ¹é»ö ·ûÀÌ ³ªÅ¸³ª¸é ´Ü¹é, ³ì»ö·ûÀÌ ³ªÅ¸³ª¸é ´ãÁó »ö¼Ò°¡ ÀÖÀ½À» ³ªÅ¸³½´Ù.
  • Becker's test
    º£Ä¿ ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
complement 1q <chemical> Subcomponent of complement 1 (c1) which recognises and binds to the heavy chain of IgG or IgM initiating the classical complement pathway. The interaction of c1q and immunoglobulin activates c1r and c1s. The activated c1r and c1s molecules are cleaved off the complex by c1-inhibitor, allowing the collagen-like region of c1q to become accessible for interaction with cell membrane c1q receptors.
Chemical name: Complement C1q
(12 Dec 1998)
complement 1r <enzyme> Subcomponent of complement 1 which, when activated by c1q, activates subcomponent c1s by proteolytic cleavage.
Registry number: EC 3.4.21.41
(12 Dec 1998)
complement 1s <enzyme> The activated form of complement 1 which has hydrolase activity. In the classical pathway, it splits first c4 and then c2 into active components, thereby generating a new enzyme referred to as eac142 or c42 or c3 convertase.
Registry number: EC 3.4.21.42
(12 Dec 1998)
complement 2 The third component in the complement reaction sequence. It is a beta-globulin with a molecular weight of 117,000, a serum concentration of 30 micrograms/ml and a sedimentation coefficient of 4. It activates c3.
(12 Dec 1998)
complement 3 The fourth component to attach in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 5.5, a molecular weight of 185,000 and a serum concentration of 1.3 micrograms/ml. Its fragments have anaphylatoxic, chemotactic, and histaminic action and affect smooth muscle.
(12 Dec 1998)
complement 3a <chemical> Smaller fragment formed when c3 convertase splits c3 into c3a and c3b. C3a is a 77-amino acid peptide that includes a carboxy-terminal arginine which is crucial for its biological activities. C3a causes symptoms of immediate hypersensitivity (anaphylaxis) including smooth muscle contraction, mast cell histamine release, and local inflammation. It is considered an anaphylatoxin along with c4a, c5a, and c5a des-arginine.
Chemical name: Complement C3a
(12 Dec 1998)
complement 3b <chemical> The larger fragment formed when c3 convertase splits c3 into c3a and c3b. In both the classical and alternate pathway, c3b participates in immune adherence and enhances phagocytosis. It also forms a cellular intermediate which continues the complement process. In the alternate pathways, c3b initiates a positive feedback activation of c3pase.
Chemical name: Complement C3b
(12 Dec 1998)
complement 3b inactivators Compounds which inhibit, antagonise, or inactivate complement 3b. A well-known inhibitor is a beta-globulin which cleaves c3b into inactive fragments c3c and c3d. C3bina plays a key role in the regulation of the complement system by blocking the cytolytic sequence and preventing recruitment of the properdin amplification loop.
(12 Dec 1998)
complement 3c <chemical> An inactivated form of complement 3b (c3b). Complement 3b is inactivated with the help of two regulatory factors, complement factor h and complement factor I. Complement factor h (c3b inactivator accelerator) makes c3b susceptible to the serine protease, complement factor I (formerly called kaf, c3binf, or enzyme 3b inactivator), to form ic3b. Then complement factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg.
Chemical name: Complement C3c
(12 Dec 1998)
complement 3 convertase <enzyme> The enzyme which in both the classical and alternate complement pathways cleaves complement 3 into anaphylatoxin (c3a) and c3b.
Registry number: EC 3.4.21.43
(12 Dec 1998)
complement 3d <chemical> An inactivated fragment of complement 3b (c3b). Factor h makes c3b susceptible to factor I (formerly called kaf, c3binf, or enzyme 3b inactivator) to form ic3b. Then factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Serum proteases degrade c3dg into complement 3d (c3d) and c3g.
Chemical name: Complement C3d
(12 Dec 1998)
complement 3 nephritic factor A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b.
(12 Dec 1998)
complement 4 The second component to react in the complement sequence. It is a beta-globulin with a sedimentation coefficient of 18.7, a molecular weight of 240,000 and a serum concentration of 430 micrograms/ml. It is activated by complement 1 and serves as a receptor for c2.
(12 Dec 1998)
complement 4a <chemical> Smaller fragment formed when c1s splits c4 into c4a and c4b. As an anaphylatoxin, c4a causes symptoms of immediate hypersensitivity but it has weaker activity than c3a or c5a.
Chemical name: Complement C4a
(12 Dec 1998)
complement 4b <chemical> Larger fragment formed when c1s splits c4 into c4a and c4b. C4b combines with c2b to form the activated c4b2b complex which is often called the classical pathway c3 convertase.
Chemical name: Complement C4b
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á